Theranostics Health, Inc.

The Company's proteomic-based molecular assay is setting the standard for the next gen of personalized diagnostics - changing the landscape of the MDx market.

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location Rockville, MD, US
  • Currency USD
  • Founded 2007
  • Employees 10
  • Website theranosticshealth.com

Company Summary

Theranostics Health provides oncologists proteomic-based molecular diagnostic assays that enable more informed therapeutic decisions. The TheraLink™ HER Family Assay delivers actionable, personalized, guidance for treating breast cancer patients by measuring signaling activity across a panel of drug targets, a technology superior to all other MDx technologies, including genomics technologies, in terms of the value and reliability of information.

Team

  • Ronald Hencin
    VP Business Devlopment

    Joined Theranostics after serving as VP of BioResearch Sales for Gene Logic, a leading provider of integrated genomics information and services. He led the business development efforts, managing direct sales to major pharmaceutical and biotech corporations worldwide. He has experience in strategic sales, sales management, coupled with experience taking start-ups through acquisitions. BS in Biology: Yale; Ph.D. in Microbiology: Univ. of Florida

  • Glenn Hoke
    President and CEO

    Joined the Company as COO Sept. 2009 and was appointed CEO in 2010. Has held several leadership positions within the biotechnology/pharmaceutical community, including: Board Member and Exec. VP/CSO Dyad Pharmaceuticals, Corp.; VP R&D Gene Logic, Inc.; VP Res. Genetic MediSyn, Corp.; Sen. Sci. Isis Pharmaceuticals, Inc.; and Sci. SKF Res. Dev. Labs. Earned BS Biol. VPI&SU, MS Biol. VCU, and his PhD Biochemistry. VCU’s Medical College of Virginia.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free